Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Forest Expects Namenda To Thrive Under Medicare Part D

This article was originally published in The Pink Sheet Daily

Executive Summary

Large cash-paying contingent of patients and sizable nursing home population should bring benefit from Part D coverage, company notes.

You may also be interested in...

Forest’s Namenda Gets “Not Approvable” Letter For Mild Alzheimer’s Indication

The firm blames supplementary studies – which found numerical improvement for the memantine cohort but failed to meet statistical significance – for the denial.

Nexavar “Very Competitive” With Pfizer’s Sutent, Bayer Says

Bayer’s kidney cancer drug brought in $25.2 mil. (€20 mil.) in the first quarter following its approval late last year.

Nebivolol Approval Could Come In Mid-2007, Forest Says

The firm is conducting small studies of short duration after meeting with FDA regarding a May 2005 “approvable” letter.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts